Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 6/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10969259 | 1.00 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3KCNH2TDP1 | |
| SCHEMBL13743615 | 1.00 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3KCNH2TDP1 | |
| SCHEMBL151181 | 0.82 | IDO1 (0.44) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3687682 | 0.82 | IDO1 (0.44) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27849319 | 0.81 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27376966 | 0.80 | IDO1 (0.42) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7294198 | 0.80 | EPHX1 (0.55) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL38651360 | 0.78 | IDO1 (0.60) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11392947 | 0.78 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL13883844 | 0.78 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090198080-A1 | METHOD FOR THE PREPARATION OF ARYL ETHERS | PFIZER INC | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090198080-A1 | METHOD FOR THE PREPARATION OF ARYL ETHERS | CYP2E1, CBR1, CYP1A1 | SLC6A2 3666/4885SLC6A4 2765/4885SLC6A3 2791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.